| 1 |
Broad targeting of resistance to apoptosis in cancer
Ramzi M. Mohammad et al. · Seminars in Cancer Biology
Open access |
28 Apr 2015 |
869 |
| 2 |
Cancer prevention and therapy through the modulation of the tumor microenvironment
Stephanie C. Casey et al. · Seminars in Cancer Biology
Open access |
11 Apr 2015 |
393 |
| 3 |
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Martin Oft · Cancer Immunology Research
|
Mar 2014 |
320 |
| 4 |
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Keith I. Block et al. · Seminars in Cancer Biology
Open access180 authors |
18 Nov 2015 |
302 |
| 5 |
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Aung Naing et al. · Cancer Cell
Open access |
Nov 2018 |
256 |
| 6 |
Accurate RNA 3D structure prediction using a language model-based deep learning approach
Tao Shen, Zhihang Hu, Siqi Sun et al. · Nature Methods
Open access |
21 Nov 2024 |
228 |
| 7 |
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets
Xintao Qiu et al. · Nature Communications
Open access |
13 May 2022 |
166 |
| 8 |
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer
Felix Yi-Chung Feng et al. · JAMA Oncology
Open access |
12 Feb 2021 |
156 |
| 9 |
Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells
Ivan H. Chan et al. · Mucosal Immunology
Open access |
27 Nov 2013 |
144 |
| 10 |
Engineering Aptamer with Enhanced Affinity by Triple Helix-Based Terminal Fixation
Lianhui Zhao, Xiaoyan Qi, Xiao-Chen Yan et al. · Journal of the American Chemical Society
|
14 Oct 2019 |
139 |
| 11 |
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing et al. · The Lancet Oncology
Open access |
25 Sep 2019 |
120 |
| 12 |
Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes
Adam Benjamin Weiner, Thiago Vidotto, Yang Liu et al. · Nature Communications
Open access |
10 Feb 2021 |
116 |
| 13 |
A multi-targeted approach to suppress tumor-promoting inflammation
Abbas K. Samadi et al. · Seminars in Cancer Biology
Open access |
5 May 2015 |
111 |
| 14 |
A generative deep learning approach to de novo antibiotic design
Aarti Krishnan et al. · Cell
Open access |
15 Aug 2025 |
92 |
| 15 |
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells
Jonathan Chou, Kai R. Trepka, Martin Sjöström et al. · European Urology Oncology
Open access |
22 Feb 2022 |
92 |
| 16 |
Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences
Walter Rayford et al. · Communications Biology
Open access |
3 Jun 2021 |
87 |
| 17 |
Deep generative design of RNA aptamers using structural predictions
Felix Wong, Dongchen He, Aarti Krishnan et al. · Nature Computational Science
Open access |
6 Nov 2024 |
83 |
| 18 |
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
Harriet M. Kluger, J. Carl Barrett, Justin F. Gainor et al. · Journal for ImmunoTherapy of Cancer
Open access |
Mar 2023 |
83 |
| 19 |
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
Isabella C. Glitza et al. · Cancer Discovery
Open access |
3 Apr 2024 |
79 |
| 20 |
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
Anis Amalina Abdul Hamid, Hsin-Chieh Huang, V. Wang et al. · Annals of Oncology
Open access |
12 Jun 2021 |
78 |
| 21 |
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
Tracy C. Kuo, Amy Yen-Chi Chen, Ons Harrabi et al. · Journal of Hematology & Oncology
Open access |
30 Nov 2020 |
76 |
| 22 |
Disagreement on foundational principles of biological aging
Vadim N. Gladyshev et al. · PNAS Nexus
Open access |
28 Nov 2024 |
63 |
| 23 |
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials
Paul Linh Nguyen et al. · International Journal of Radiation Oncology*Biology*Physics
ReviewOpen access |
31 Dec 2022 |
55 |
| 24 |
Pegylated IL ‐10 induces cancer immunity
John Brian Mumm, Martin Oft · BioEssays
Review |
13 May 2013 |
53 |
| 25 |
Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars
Kristof Vandekerckhove, Andreas Seidl, Hiten J. Gutka et al. · The AAPS Journal
Open access |
10 May 2018 |
47 |
| 26 |
Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics
Karen A. Autio, Martin Oft · Current Oncology Reports
|
Feb 2019 |
46 |
| 27 |
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
J.A. Marascio et al. · Prostate Cancer and Prostatic Diseases
Open access |
12 Nov 2019 |
45 |
| 28 |
Rational Design of Liquid Formulations of Proteins
Mark Cornell Manning, Jun Liu, Tiansheng Li et al. · Advances in protein chemistry and structural biology
Book chapter |
2018 |
41 |
| 29 |
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
Felix Yi-Chung Feng, Shibu Thomas, Fred Saad et al. · JAMA Oncology
Open access |
3 Jun 2021 |
40 |
| 30 |
Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases
Paul J. Sampognaro, Shruti Arya, Giselle M. Knudsen et al. · Molecular Neurodegeneration
Open access |
2 May 2023 |
38 |
| 31 |
The Potentiation of IFN-γ and Induction of Cytotoxic Proteins by Pegylated IL-10 in Human CD8 T Cells
Ivan H. Chan, Victoria H. Wu, Melissa Bilardello et al. · Journal of Interferon & Cytokine Research
|
26 Aug 2015 |
37 |
| 32 |
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells
Narendiran Rajasekaran, Xiaoguang Wang, Sruthi Ravindranathan et al. · Cancer Immunology Immunotherapy
Open access |
24 Feb 2024 |
33 |
| 33 |
Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation
Richard Zang, Aline Barth, Harvey Wong et al. · Journal of Medicinal Chemistry
|
5 Jul 2022 |
32 |
| 34 |
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens
Zev A. Wainberg, Kynan Feeney, Myung Ah Lee et al. · BMC Cancer
Open access |
8 Jul 2020 |
32 |
| 35 |
Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs
Francesca Civoli, Aparna Kasinath, Xiaoyan Cai et al. · The AAPS Journal
|
2 Dec 2019 |
31 |
| 36 |
Potential Anticancer Properties and Mechanisms of Action of Withanolides
Abbas K. Samadi · The Enzymes
Book chapter |
2015 |
31 |
| 37 |
Neutralizing Antibody Validation Testing and Reporting Harmonization
Heather A. Myler et al. · The AAPS Journal
Open access |
8 Jul 2023 |
30 |
| 38 |
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab
Andrea Necchi, Joep J. de Jong, Daniele Raggi et al. · European Urology
|
27 Mar 2021 |
29 |
| 39 |
Short-Acting Testosterone: More Physiologic?
Gerwin Westfield, Ursula B. Kaiser, Dolores J. Lamb et al. · Frontiers in Endocrinology
Open access |
30 Sep 2020 |
28 |
| 40 |
An explainable deep learning platform for molecular discovery
Felix Wong, Satotaka Omori, Alicia Li et al. · Nature Protocols
|
9 Dec 2024 |
27 |
| 41 |
A comparative study of PCS and PAM50 prostate cancer classification schemes
Junhee Yoon, Minhyung Kim, Edwin Melencio Posadas et al. · Prostate Cancer and Prostatic Diseases
Open access |
2 Feb 2021 |
27 |
| 42 |
Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer
Amar Upadhyaya Kishan et al. · European Urology
Open access |
23 May 2020 |
27 |
| 43 |
Risk‐Based Pharmacokinetic and Drug–Drug Interaction Characterization of Antibody–Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective
Chunze Li, Rajeev M Menon, Markus Walles et al. · Clinical Pharmacology & Therapeutics
|
19 Oct 2021 |
25 |
| 44 |
Improved DNA Extraction and Amplification Strategy for 16S rRNA Gene Amplicon-Based Microbiome Studies
Bo‐Young Hong, Mark D. Driscoll, Dawn Gratalo et al. · International Journal of Molecular Sciences
Open access |
4 Mar 2024 |
22 |
| 45 |
Isoform separation of proteins by mixed-mode chromatography
Tsutomu Arakawa, Sean Ponce, Glen W. Young · Protein Expression and Purification
|
13 Aug 2015 |
22 |
| 46 |
High-resolution microbiome analysis reveals exclusionary Klebsiella species competition in preterm infants at risk for necrotizing enterocolitis
Spencer Coleman, Katrin Unterhauser, Karim Rezaul et al. · Scientific Reports
Open access |
16 May 2023 |
21 |
| 47 |
Cancer research in the United States: A critical review of current status and proposal for alternative models
Hagop M. Kantarjian, Ferran Prat, David P. Steensma et al. · Cancer
Open access |
14 May 2018 |
21 |
| 48 |
Statistical Approaches to Assess Biosimilarity from Analytical Data
Richard K. Burdick, Todd S. Coffey, Hiten J. Gutka et al. · The AAPS Journal
|
5 Oct 2016 |
20 |
| 49 |
Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer
Yuki Yoshikawa, Konrad Hermann Stopsack, Victoria Wang et al. · Molecular Oncology
Open access |
10 Sep 2022 |
19 |
| 50 |
The Selective Peroxisome Proliferator‐Activated Receptor Gamma Modulator CHS‐131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis
Nikolaos Perakakis, Aditya Joshi, Natia Peradze et al. · Hepatology Communications
Open access |
28 Jul 2020 |
19 |